Speciality Medicines Expands to Ethiopia with New Drug Approvals
By ThePip Desk
Speciality Medicines gains Ethiopian regulatory approval for Olanzapine and Diazepam formulations, expanding its international portfolio to 12 products and strengthening its African market presence.
Speciality Medicines has secured critical regulatory approval from the competent health authority in Ethiopia for two new speciality pharmaceutical formulations. This strategic move significantly bolsters the company’s international product portfolio and underscores its continued progress in regulatory registrations across key export markets.
New Formulations Drive Portfolio Growth
The newly approved products are integral to the company’s expansion efforts within the African market. These additions reflect a deliberate and successful push to broaden its therapeutic reach and market presence.
- Olanzapine Tablets 5 mg (marketed as Olazyn 5)
- Diazepam Tablets 5 mg (marketed as Diazem 5)
Key International Footprint Numbers
These latest approvals cement Speciality Medicines’ growing presence, particularly within the Ethiopian market. The company’s international registration strategy continues to show tangible progress across multiple continents, including Latin America.
- Total registered product portfolio in Ethiopia now stands at: 12 formulations
- Established presence in Peru with: 2 registered formulations
Strategic Expansion in Complex Therapeutics
Speciality Medicines primarily focuses on the marketing and distribution of finished formulations of specialty pharmaceutical products. These include high-cost oral and injectable medications, addressing critical patient needs.
The company specifically targets complex and chronic medical conditions, operating within crucial therapeutic areas. These include oncology, immunology, neurology, and rare diseases, aligning with its global expansion drive across Africa and Latin America.